Edition:
United States

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

1.83USD
25 Apr 2018
Change (% chg)

$0.01 (+0.55%)
Prev Close
$1.82
Open
$1.82
Day's High
$1.85
Day's Low
$1.78
Volume
14,558
Avg. Vol
104,287
52-wk High
$4.09
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Sierra Oncology Announces Pricing Of Public Offering Of Common Stock
Friday, 2 Mar 2018 09:03am EST 

March 2 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 19.0 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.  Full Article

Sierra Oncology Announces Proposed Public Offering Of Common Stock
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SIERRA ONCOLOGY - INTENDS TO USE NET PROCEEDS FROM PUBLIC OFFERING TO FUND DEVELOPMENT OF ITS PRODUCT CANDIDATES, SRA737 AND SRA141.  Full Article

Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share
Tuesday, 27 Feb 2018 07:10am EST 

Feb 27 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY REPORTS 2017 YEAR END RESULTS.SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20‍​.SIERRA ONCOLOGY - ‍BELIEVES EXISTING CASH, CASH EQUIVALENTS TO BE SUFFICIENT TO FUND CURRENT OPERATING PLANS THROUGH ABOUT MID-2019​.SIERRA ONCOLOGY INC - CASH AND CASH EQUIVALENTS TOTALED $100.3 MILLION AS OF DECEMBER 31, 2017, COMPARED TO $107.8 MILLION AS OF SEPTEMBER 30, 2017‍​.  Full Article

Sierra Oncology Significantly Expands Clinical Development Program
Tuesday, 27 Feb 2018 07:05am EST 

Sierra Oncology Inc ::SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM.SIERRA ONCOLOGY INC - ADDING NEW SRA737 MONOTHERAPY COHORT FOR CCNE1-DRIVEN OVARIAN CANCER.SIERRA ONCOLOGY INC - SRA141 IND SUBMISSION PLANNED IN H2 2018.SIERRA ONCOLOGY - ONGOING SRA737 CLINICAL STUDIES EXPANDED TO TARGET AGGREGATE ENROLLMENT OF 200 PATIENTS ACROSS TEN CANCER INDICATIONS.SIERRA ONCOLOGY - TO INITIATE PHASE 1B/2 TRIAL IN Q4 TO EVALUATE SRA737 WITH ZEJULA TO TREAT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.SIERRA ONCOLOGY - EXPANDING NUMBER OF ACTIVE SITES RECRUITING PATIENTS INTO SRA737-01 PHASE 1/2 MONOTHERAPY TRIAL FROM 3 TO 15.SIERRA ONCOLOGY - MAJORITY OF REPORTED ADVERSE EVENTS IN SRA737-02 PHASE 1/2 LDG COMBINATION TRIAL HAVE BEEN GRADE 1 OR GRADE 2 IN SEVERITY.SIERRA ONCOLOGY - ONLY ONE GRADE 3 TREATMENT RELATED AE (NEUTROPENIA) WAS OBSERVED, AT 40 MG SRA737/300 MG/M(2) GEMCITABINE.  Full Article

Sierra Oncology reports net loss $0.19 per share
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Sierra Oncology Inc ::Sierra Oncology reports third quarter results.Qtrly ‍net loss per share, basic and diluted $0.19​.  Full Article

Sierra Oncology reports qtrly loss per share $‍0.20​
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Sierra Oncology Inc :Sierra Oncology reports second quarter 2017 results.‍on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018​.‍$116.7 million cash at June 30, 2017 projected to fund current operating plans through approximately mid-2019​.Qtrly loss per share $‍0.20​.  Full Article

Sierra Oncology reports initial progress from phase 1 clinical trials of CHK1 inhibitor SRA737
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Sierra Oncology Inc :Sierra oncology reports encouraging initial progress from ongoing phase 1 clinical trials of chk1 inhibitor sra737.Sierra oncology inc says sra737 has been well-tolerated to date.Sierra oncology inc - "no grade 2 or higher sra737-related adverse events have been reported".Sierra oncology inc says for phase 1 chemotherapy combination study, has concluded enrolment and study has transitioned to stage 2.Sierra oncology inc - sra737 development program remains on track.  Full Article

Sierra Oncology granted U.S., EU patents for CHK1 inhibitor SRA737
Tuesday, 30 May 2017 07:00am EDT 

May 30 (Reuters) - Sierra Oncology Inc :Sierra Oncology granted U.S. and EU patents for CHK1 inhibitor SRA737.  Full Article

Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Sierra Oncology Inc : :Says received clearance from regulators in UK to amend two ongoing phase 1 trials for its CHK1 inhibitor, SRA737.Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737.Says amended trials will include cohort expansions of prospectively selected patients with tumors.Says an initial update from these trials is anticipated in early 2018.Says study will now consist of two phases, a dose escalation phase and a cohort expansion phase, being run concurrently.  Full Article

Sierra Oncology Inc Q1 net loss per share $0.26
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Sierra Oncology Inc :Sierra Oncology reports first quarter 2017 results.Sierra Oncology Inc - qtrly net loss per share $0.26.Q1 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sierra Oncology - believes its existing cash and cash equivalents will be sufficient to fund current operating plans through approximately mid-2019.  Full Article